Milk Thistle (Siliphos)
Also sold as: Milk Thistle (Silymarin), Silymarin, Siliphos (Silybin Phytosome)
Best-in-class: Siliphos
Milk thistle's active silybin in an absorption-enhanced phytosome — the premier botanical for liver protection and regeneration.
Milk Thistle (Siliphos) quick facts
| Suggested dose | As directed. |
| How often | Daily |
| Who it's for | Liver protection and support — the strongest single-herb liver option. |
The mushroom-poisoning use is the strongest evidence that the mechanism is real. Oral evidence in liver disease is more mixed, and bioavailability is the reason — plain silymarin absorbs poorly, which is what the phytosome formulation addresses and what the better trials used. It inhibits some CYP enzymes. Genuinely one of the better-founded liver supplements.
How Milk Thistle (Siliphos) actually works
Silybin stabilizes hepatocyte membranes against toxin penetration, stimulates ribosomal RNA polymerase to accelerate regeneration, and inhibits the transporter that carries amanitin into liver cells. That last mechanism is why intravenous silibinin is the established antidote for death-cap mushroom poisoning — a serious demonstration that this is a real pharmacological agent.
Where to get Milk Thistle (Siliphos)
Buy Siliphos at Thorne →What it is, why it recurs, and where this fits — free to read.
The evidence for Milk Thistle (Siliphos)
Graded by what exists behind each claim.
✅ Clinically validated
- Silybin/silymarin has RCT support for improving liver enzymes and hepatocyte protection.
- The phytosome dramatically improves milk thistle's otherwise poor absorption.
📊 Correlative data
- Liver stress markers track with alcohol, medication and metabolic load.
🧪 Theoretical / extrapolated benefits
- Antioxidant and regenerative mechanisms are well-characterized; broad 'detox' claims are looser.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Milk Thistle (Siliphos) actually does
Silymarin is not a compound, it is a fraction, and the proportions differ by seed lot. Extract of Silybum marianum fruit yields a mixture of flavonolignans — silybin A and silybin B in roughly equal amounts, isosilybin A and B, silychristin, silydianin — plus taxifolin and a large amount of undeclared fatty and polyphenolic material. Silybin is usually treated as the active and typically makes up 50 to 70 percent of the flavonolignan content, which means a product standardized to 80 percent silymarin has declared the fraction and not the molecule Javed 2011.
The membrane-stabilizing mechanism is the oldest claim and the one with the least human support. Silybin partitions into the hepatocyte membrane and is proposed to block the binding site that amatoxins from Amanita phalloides use to enter through the sodium-taurocholate cotransporting polypeptide. That is a specific, testable transporter argument and it belongs to intravenous silibinin in mushroom poisoning, not to a capsule taken for fatty liver.
The antioxidant and signaling mechanisms are the ones that produce a laboratory result. Silybin scavenges reactive species, raises hepatic glutathione, inhibits nuclear factor kappa B translocation, and suppresses stellate cell activation and collagen transcription in culture. Every one of those is a mechanism for less transaminase leakage rather than for a better liver, and that distinction is what this page is about.
ALT is not a measure of liver function. It is a measure of hepatocyte membrane leak. Alanine aminotransferase sits in the cytosol and appears in serum when membranes are damaged. A compound that stabilizes membranes lowers the enzyme that leaks through them without necessarily changing fibrosis, steatosis or the synthetic capacity that decides whether a liver fails. That is the surrogate at the center of this product.
There is also a real drug-metabolism story. Silybin and its conjugates inhibit UDP-glucuronosyltransferase and, at high concentrations, several cytochrome P450 isoenzymes, and it is a substrate and inhibitor of organic anion transporting polypeptides. That is the mechanism behind the interaction section below, and it is better documented than the efficacy.
Cell, rodent, human — and where it stops
The chain runs from a genuinely impressive in vitro pharmacology to a human literature that keeps returning the same modest number for the same enzyme.
In cells and rodents the protection is reproducible. Silybin protects hepatocytes against carbon tetrachloride, galactosamine, acetaminophen and ethanol in standard models, and reduces fibrosis markers in bile duct ligated rats. Those models deliver the compound at concentrations that oral dosing in a person does not achieve, which is the first obstacle and the largest.
In humans the enzyme moves a little. Systematic review of the randomized literature finds silymarin supplementation associated with reductions in alanine and aspartate aminotransferase across mixed liver conditions Calderon Martinez 2023, and a meta-analysis of trials targeting liver injury reaches a comparable conclusion while arguing that dose and preparation practices need revisiting Shahsavari 2025. So the marker does respond.
The best-designed trial gave three to five times the usual dose and got nothing. In patients with chronic hepatitis C who had failed interferon, oral silymarin at 420 mg or 700 mg three times daily for 24 weeks produced no reduction in serum alanine aminotransferase and no reduction in hepatitis C virus RNA compared with placebo Fried 2012. That trial is the reason the positive meta-analyses should be read carefully: it used more drug than any product on a shelf and it moved neither the surrogate nor the disease.
And in the condition most people buy it for, the systematic answer is uncertainty. The Cochrane assessment of silymarin for adults with metabolic dysfunction-associated steatotic liver disease finds the evidence too limited and too low in certainty to establish benefit on clinical outcomes Wang 2025. The obstacle to transfer here is not species or dose. It is that almost every trial used aminotransferases as the endpoint, and nobody has followed anyone to cirrhosis, decompensation or death.
Milk Thistle (Siliphos) — which form, and does it matter
The reason the trials and the shelf disagree is that silymarin is almost insoluble and almost unabsorbed. Absolute oral bioavailability of silybin from a standard extract is on the order of a few percent. Peak plasma concentration arrives at roughly 1 to 2 hours, and the compound is cleared with a half-life of about 4 to 6 hours — short enough that three-times-daily dosing was not an arbitrary choice in the trials Wen 2008.
What limits exposure is not absorption alone but conjugation immediately behind it. Silybin undergoes extensive first-pass phase II metabolism, principally glucuronidation and sulfation in the enterocyte and hepatocyte, so most of what reaches plasma circulates as conjugate rather than free flavonolignan. Elimination is largely biliary with enterohepatic recycling rather than renal clearance, which is why urinary recovery is low and why measuring the parent compound underestimates total exposure Wen 2008.
The phytosome is a genuine pharmacokinetic advance and a genuine evidence gap. Complexing silybin with phosphatidylcholine raises measured exposure several-fold over unformulated extract Javed 2011. That is the product this catalog carries. It also means the product on the shelf is not the material in the hepatitis C trial, in either direction: the trial used far more silymarin at far lower absorption, and no equivalently sized outcome trial has been run on the phytosome.
The two silybin diastereomers are not interchangeable and no label reports their ratio. Silybin A and silybin B differ in conjugation rate and in potency in several assays, and the ratio varies with seed source and extraction. A product declaring milligrams of silymarin has said nothing about which diastereomer profile it contains.
Practical consequence. Dose comparisons across this literature are almost meaningless unless the preparation is named. 140 mg of a phytosome, 140 mg of an 80 percent standardized extract and 140 mg of ground seed are three different exposures, and the systematic reviews are pooling them Shahsavari 2025.
What would have to be true, and how you would know it was not
1. Predict a modest ALT fall and treat it as the product's own claim, not as evidence of a better liver. On a phytosome at label dose, predict GGT (gamma-glutamyl transferase) and ALT down by a small margin over 8 to 12 weeks in somebody whose enzymes were raised, and no change at all in somebody whose enzymes were normal Calderon Martinez 2023. Retest a comprehensive metabolic panel at 12 weeks.
2. Predict the tests that describe liver FUNCTION do not move. Albumin, bilirubin, platelet count and prothrombin activity are the quantities that fall when a liver is actually failing. Predict no change in any of them. If a product is going to be sold for liver support, those are the numbers it should be judged on, and no trial has shown it moves them.
3. The prediction that cuts against the product. Predict that a trial giving 2 grams a day of silymarin for six months to people with chronic liver disease returns no change in histology, because the closest thing to that trial returned no change in the enzyme either Fried 2012. A randomized trial of the phytosome with paired biopsy or with the enhanced liver fibrosis (ELF) score as the endpoint, showing improvement, would falsify this page.
4. Predict the fibrosis score, not the enzyme, is where a real effect would have to appear. Non-invasive fibrosis measures — ELF score, transient elastography — move slowly and are the honest endpoint for a hepatoprotective claim. Predict no change at 12 months, and set that as the test rather than a transaminase drawn at 6 weeks Wang 2025.
5. Predict an interaction before predicting a benefit. If somebody takes a drug cleared by glucuronidation, predict a measurable change in that drug's concentration before predicting a change in their liver. That is the more likely detectable effect of this supplement, and it is the reverse of how it is marketed.
What nobody has tested yet
The phytosome has never been tested at the endpoint that matters. The formulation solves the absorption problem the trials blamed for failure, and no adequately powered trial has then used it against histology or fibrosis Javed 2011 Wang 2025. That is the most obvious unrun study in this entire catalog.
Nobody knows which flavonolignan to standardize on. Silychristin is a potent inhibitor of a thyroid hormone transporter in vitro; isosilybin A is more active than silybin in some anti-proliferative assays. Products are standardized on total silymarin because that is the assay that exists, not because it is the right one.
The intravenous and oral literatures have never been reconciled. Intravenous silibinin is a recognized treatment for amatoxin poisoning; oral silymarin is a supplement with an equivocal record. Whether the difference is entirely exposure or partly indication has not been established, and it is the strongest argument either way Wen 2008.
And nobody has published a market survey. No study has bought thirty on-market milk thistle products and reported flavonolignan content and diastereomer ratio by high performance liquid chromatography against label claim. Until that exists, dose recommendations for this plant are recommendations about a label rather than about a material Shahsavari 2025.
Milk Thistle (Siliphos) — its own safety story, not its category's
Direct toxicity is low and that is well established. Even at 2.1 grams a day for six months, the adverse event profile did not differ meaningfully from placebo Fried 2012. Loose stools, bloating and nausea are the common complaints and are dose-related. Anaphylaxis has been reported and is a plant-family event: Silybum is an Asteraceae, so ragweed, chrysanthemum and daisy sensitivity is the relevant history to ask about.
The real risk on this page is pharmacokinetic, not toxicologic. Silybin conjugates inhibit UDP-glucuronosyltransferase and organic anion transporting polypeptides, and at higher concentrations several cytochrome P450 isoenzymes. Drugs cleared by glucuronidation — raltegravir, lamotrigine, mycophenolate, irinotecan's active metabolite — are the ones where a change in exposure is most plausible.
Two specific combinations deserve naming. Milk thistle taken alongside a statin raises a theoretical transporter interaction because both use organic anion transporting polypeptide 1B1 for hepatic uptake. And silymarin has been reported to lower blood glucose in people with type 2 diabetes, which is additive with insulin and sulfonylureas rather than independent of them.
The harm that is easiest to overlook is delay. A person with unexplained transaminase elevation who takes a liver supplement for six months instead of establishing a cause has not been protected from anything. Hepatitis B and C, hemochromatosis, autoimmune hepatitis, alcohol and drug injury all present with the same modest ALT rise this product is bought to lower Wang 2025.
Who should not take it. Pregnancy and lactation have no safety data at supplemental doses. Anyone with a hormone-sensitive condition should note that some silymarin components have weak estrogenic activity in vitro. And anyone whose liver enzymes are abnormal enough to be worth treating is someone whose enzymes are abnormal enough to be worth diagnosing. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.
Sources read for this page
- Fried MW. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy. JAMA 2012 · PMID 22797645
- Wen Z. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metabolism and Disposition 2008 · PMID 17913795
- Javed S. Reassessing bioavailability of silymarin. Alternative Medicine Review 2011 · PMID 21951025
- Wang C. Silymarin for adults with metabolic dysfunction-associated steatotic liver disease. Cochrane Database Syst Rev 2025 · PMID 40552569
- Calderon Martinez E. Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review. Cureus 2023 · PMID 38021897
- Shahsavari K. Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury. BMC Complement Med Ther 2025 · PMID 40221681
How you would know if it worked
These are the markers that recommend this product on their own pages, so they are the ones that should move if it is doing what it is sold for.
- Comprehensive Metabolic Panel (CMP) — Omega-3s, vitamin E (in NAFLD), TUDCA 250–500 mg (used by those on hepatotoxic orals), NAC, milk thistle (modest evidence) Retest: Every 3–6 months on any oral compound; annually otherwise.
- GGT (Gamma-Glutamyl Transferase) — Silybin (milk thistle) has real but modest evidence Retest: 6 weeks minimum after any change, because of the 2–3 week half-life. Sooner than that and you are measuring the previous month. Every 6–12 months as routine if you drink, carry visceral fat, or run oral compounds.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Milk Thistle (Siliphos) — safety & side effects
- GI upset and a mild laxative effect are the common reports; it is otherwise very well tolerated.
- Allergy in people sensitive to ragweed, daisies and marigolds — same family.
- Inhibits some CYP enzymes and can raise levels of medications cleared that way. May lower blood glucose.
- It does not make it safe to drink more. That is the misuse worth naming.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Milk Thistle (Siliphos) in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Milk Thistle (Siliphos)
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | ALT and AST. The evidence is weaker than the marketing — measure, don't assume |
| Enhanced Liver Fibrosis (ELF) Test | Fibrosis staging, which enzymes alone cannot give you |
The Fatty Liver & Liver Health panel covers these in one order — 8 markers, $291.15 with the discount applied.
Check results you already have → · All 103 markers A–Z
Milk Thistle (Siliphos) — frequently asked questions
What is Milk Thistle (Siliphos)?
Milk thistle's active silybin in an absorption-enhanced phytosome — the premier botanical for liver protection and regeneration.
What is the suggested dose of Milk Thistle (Siliphos)?
As directed. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Milk Thistle (Siliphos) dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Milk Thistle (Siliphos)?
Coach Cam sources Milk Thistle (Siliphos) from Thorne, with 10% off auto-applied at checkout — use the buy link on this page.
Milk Thistle (Siliphos) inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Milk Thistle (Siliphos) is used for
Milk Thistle (Siliphos) appears under 3 goals in the goal router.
Related Immune & Detox supplements
Where this goes next
Milk Thistle (Siliphos) is the hepatic arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.